We aimed to determine the risk of alopecia areata (AA) and vitiligo associated with atopic dermatitis (AD) in a large cohort of US women, the Nurses' Health Study 2. We used logistic regression to calculate age-and multivariate-adjusted odds ratios to determine the risk of incident AA and vitiligo associated with AD diagnosed in or before 2009. A total of 87 406 and 87 447 participants were included in the AA and vitiligo analyses, respectively. A history of AD in 2009 was reported in 11% of participants. There were 147 incident cases of AA and 98 incident cases of vitiligo over 2 years of follow-up. AD was associated with increased risk of developing AA (OR 1.80, 95% CI 1.18-2.76) and vitiligo (OR 2.14, 95% CI 1.29-3.54) in multivariate models. In this study of US women, AD was associated with increased risk of incident vitiligo and AA in adulthood.
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Atopic dermatitis (AD) is a chronically relapsing skin disease characterized by skin barrier defects and Th2 and Th22 inflammation (1) . Alopecia areata (AA) is a nonscarring form of hair loss characterized by autoimmune attack on the bulb of the hair follicle. Inflammation in AA is also characterized by Th2 cytokine production, in addition to Th1, IL-23, and IL-9/TH9 (2). Vitiligo is characterized by depigmentation of the skin, with predominantly Th1-mediated inflammation (3) .
A systematic review and meta-analysis found that a history of AD increased the odds of having AA and vitiligo by over 2.5 and 7.5 times, respectively (4). However, because most included studies lacked control groups, the meta-analysis for AA was based on only three studies with 6460 cases and fewer than 10 000 participants combined, and the meta-analysis for vitiligo was based on only two studies with 85 cases and fewer than 4000 participants combined. Further, the included studies for AA comprised one case-control study (5) and two cross-sectional studies (6, 7) and the two vitiligo studies were both cross-sectional (8, 9) . A more recent large cross-sectional study based on healthcare claims data from (10) . We aimed to conduct the first prospective study examining the association of incident AA and vitiligo with AD in the Nurses' Health Study 2 (NHS2).
Methods

Population
NHS2 is an ongoing prospective cohort study of female US registered nurses established in 1989 when 116 430 participants completed a baseline questionnaire with questions about demographic and lifestyle factors, anthropometric variables, and disease history. Follow-up questionnaires are sent biennially to participants, updating information on diseases, anthropometric factors, and other risk factors. This study was approved by the institutional review board of Brigham and Women's Hospital.
Assessment of exposure, outcome, and covariates
Atopic dermatitis was first assessed in 2009, when participants were asked whether they 'ever had clinician-diagnosed eczema (atopic dermatitis)'. In 2013, participants were again asked about a history of clinician-diagnosed AD, in addition to the year they were diagnosed in intervals (before 1995, 1995-2002, 2003-2008, 2009-2010 Race/ethnicity, height and sunburn susceptibility were assessed at cohort baseline. Information on body weight, physical activity, smoking status, alcohol intake, menopausal status, and hormone replacement use have been collected and updated during cohort follow-up.
Statistical analysis
A total of 94 030 participants returned the 2011 biennial questionnaire. We excluded participants missing data on AD and AA or vitiligo for their respective analyses. This left 87 406 and 87 447 participants in the AA and vitiligo analyses, respectively.
We used logistic regression models to calculate age-and multivariate-adjusted OR and 95% CI for the association between lifetime history of AD up to 2009 and incident AA and vitiligo. A multivariate analysis was conducted adjusting for age (per 1 year, as a continuous variable), race/ethnicity (White, Hispanic, Asian, or Black), body mass index (BMI; <19, 19-21.9, 22-24.9, 25-29.9, 30-34.9, or ≥35 kg/ m 2 ), alcohol intake (0, 0.1-4.9, 5-9.9, >10 g/day), physical activity (by quintile in metabolic equivalent hours/week), cigarette smoking status [never, past, or current in cigarettes/day (≤15, 15+)], and history of postmenopausal hormone replacement use (premenopausal, postmenopausal and never used, postmenopausal and current use, and postmenopausal and past use). Age, race, BMI, alcohol intake, physical activity, and cigarette smoking have all been associated with AD in previous studies and have therefore been included in the models. Postmenopausal hormone use was included as it is a common exposure in this cohort (see Table 1 ) and has been associated with various immune alterations (11) . An indicator variable was created for the missing data of each covariate. We used covariate information from 2009 (with the exception of height and race) for this analysis.
Sensitivity analyses were conducted additionally adjusting for susceptibility to sunburn and limiting to White participants only. Andersen et al. found that a history of smoking significantly increased the association between AD and various autoimmune comorbidities, so we conducted analyses stratified by smoking status (never vs ever smokers). Interaction tests were used to determine statistical significance.
All statistical analysis was performed with SAS, version 9.2 (SAS Institute, Inc., Cary, NC, USA). A two-tailed P < 0.05 was considered statistically significant.
Results
Characteristics of the study population in the AA analysis by history of AD in 2009 are presented in Table 1 . Atopic dermatitis cases and noncases were similar with respect to major characteristics. There were no material differences between the populations included in the AA and vitiligo analyses (data not shown).
Between 2009 and 2011, there were 147 incident cases of AA and 98 incident cases of vitiligo. Atopic dermatitis was associated with increased risk of developing AA (OR 1.80, 95% CI 1.18-2.76) and vitiligo (OR 2.14, 95% CI 1.29-3.54) in multivariate models over the 2-year study follow-up (Table 2 ). In the stratified analyses by smoking status, we did not find statistically significant effect modification by eversmoking status on the association of AD with AA [OR (95% CI) 1 In sensitivity analyses using only AD cases diagnosed before 2002, the multivariate-adjusted risk of AA (OR 1.85, 
Discussion
In the present analysis, AD is a risk factor for developing AA and vitiligo in adulthood. This provides further evidence that these conditions are frequently comorbid, and ours is the first large study to prospectively determine the risk of AA and vitiligo in AD. Our sensitivity analysis including only those cases of AD diagnosed before 2002 strengthens our conclusions that AD is a risk factor for the development of AA and vitiligo later in life. While these three immune-mediated diseases are etiologically distinct, their association does have therapeutic implications. Atopic dermatitis, AA, and vitiligo have been reported to respond to inhibition of the JAK-STAT pathway, and so, patients with more than one of these diseases may specifically benefit from that therapeutic approach (12) (13) (14) . Furthermore, patients with AD and AA may respond to ustekinumab, an anti-p40 IL-12/23 monoclonal antibody (15, 16) .
Our study is strengthened by the well-established cohort with high-quality data on participant characteristics and outcomes, but is limited by its reliance on self-report of AD, AA, and vitiligo. Additionally, hypopigmentation may occur as a result of AD or topical corticosteroid use, which may result in misclassification of vitiligo cases. While this is a prospective study, elements of it are retrospective, including participants' recall of their date of cutaneous disease diagnosis. While our sensitivity analysis is reassuring with regard to reverse-causation bias, the short follow-up time limited our ability to do a lag analysis and limited the number of incident cases of AA and vitiligo. Detection bias is another concern whenever two dermatologic diseases are associated. The inclusion of women only and the racial/ethnic homogeneity of NHS2 limit the generalizability of our results.
In conclusion, in this study of US women, history of AD increased the risk of developing AA and vitiligo in adulthood.
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